0001104659-26-037701
SEC filingSoligenix’s FY2025 results reflect targeted late-stage pipeline R&D investment, with flat year-over-year revenue, widening net losses, and improved diluted EPS.
The 34% YoY increase in net loss to $11.1M in FY2025 is primarily attributable to planned R&D investments in Soligenix’s lead late-stage programs. The company ramped up spending on the confirmatory Phase 3 FLASH2 trial for its cutaneous T-cell lymphoma (CTCL) candidate HyBryte™, as well as the Phase 2a trial for its Behçet’s Disease (BD) candidate SGX945, which completed in 2025 with positive efficacy signals. The 100% YoY drop in gross profit to $0 aligns with the conclusion of a zero-margin grant supporting the HyBryte investigator-initiated study, while overall revenue remained flat YoY at $119.4K as remaining grant activity generated no margin. The 57% YoY improvement in diluted EPS to -$2.14, despite wider net losses, stems from an expanded outstanding common share count from financing activities completed during the year, which spread the loss base across a larger share count.
The company expects to continue generating losses for the foreseeable future, with its liquidity needs largely dependent on budgeted operational expenditures related to the advancement of its product candidates. Failure to obtain adequate capital when needed may force the company to delay, reduce, or eliminate business development efforts, negatively impacting its ability to achieve operational objectives, remain competitive, and maintain its financial condition and operating results. Macroeconomic and geopolitical uncertainties may further restrict access to capital, exacerbating potential liquidity challenges.
The primary value driver for investors over the next 12 months is the Phase 3 FLASH2 trial for HyBryte™, with interim results expected in Q2 2026 and top-line results in the second half of 2026. Positive data from this trial would support regulatory submissions for the CTCL candidate, which has already received Orphan Drug and Fast Track designations from the FDA, as well as promising results from earlier Phase 3 trials. The recently completed Phase 2a trial for SGX945 in BD also demonstrated efficacy comparable to the only approved therapy for the indication, with an improved safety profile and durable benefit after treatment cessation, supporting potential advancement to later-stage trials if funding is secured.